Is the Bellamy's takeover a signal to invest in infant formula?

Yesterday, Bellamy's Australia Ltd (ASX: BAL) received a takeover bid at a price of $13.25 per share. Is now the time to invest in infant formula?

| More on:
a woman

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

On Monday it was announced that China Mengniu Dairy Company had made a takeover bid for Bellamy's Australia Ltd (ASX: BAL) at a price of $13.25 per share. This price represented a 59% premium compared to the last close price of $8.32. Unsurprisingly, this news caused the price of Bellamy's shares to skyrocket.

If the takeover is successful, Bellamy's shares will no longer trade on the ASX. However, for Australian investors looking to gain exposure to the growing infant formula market there are still plenty of other options. These include A2 Milk Company (ASX: A2M), Bubs Australia Ltd (ASX: BUB), Synlait Milk Ltd (ASX: SM1) and Wattle Health Australia Ltd (ASX: WHA).

Is it the right time to invest in infant formula?

Prior to the Bellamy's takeover announcement, I did not believe the market price for Bellamy's shares constituted good value and therefore I would not have recommend investing. I hold a similar view for the remaining infant formula companies listed on the ASX. I am also concerned by the level of competition present in this industry.

The ASX listed infant formula companies must compete with a host of international competitors including Nestle, the world largest producer of infant formula. This is bad news for investors as competition usually drives down prices, margins and earnings of competing companies. Smaller companies can also be driven out of business by larger companies, which can survive for longer on lower margins.

Some of the ASX listed infant formula companies have attempted to distinguish themselves from the competition and I believe this is a smart move. a2 milk, for example, specialises in A1 protein-free milk products while Bubs' infant formula is derived from goats' milk. Unfortunately, it's hard to know at this stage if this product differentiation will lead to any form of long-term competitive advantage.

Foolish takeaway

ASX listed infant formula companies do have an opportunity to grow sales and earnings as they expand overseas. However, I would not recommend investing due to shares prices which, in my opinion, do not accurately reflect the challenges these companies face from heavy competition.

Investing in Clover Corporation Limited (ASX: CLV) might be a worthwhile alternative investment if a sensible price becomes available. Part of Clover's business is selling nutritional powders for use in infant formula. An investment would therefore offer exposure to this growing industry but from a slightly different perspective.

Mitchell Perry has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. owns shares of Clover Limited. The Motley Fool Australia owns shares of A2 Milk. The Motley Fool Australia has recommended BUBS AUST FPO. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Share Market News

A man clenches his fists in excitement as gold coins fall from the sky.
Broker Notes

These ASX 300 shares could rise 35% to 65%

Analysts are tipping these shares to rise strongly from current levels. How high could they go?

Read more »

a man in a high visibility vest and hard hat holds a thumbs up at a mine site with heavy equipment in the background.
Broker Notes

What are brokers saying about BHP shares following the miner's quarterly results?

Analysts have crunched the numbers.

Read more »

A young girls clings in fright to a big red slide.
Share Market News

Here are the top 10 ASX 200 shares today

Investors were hitting the sell button hard today...

Read more »

A man in his 30s holds his laptop and operates it with his other hand as he has a look of pleasant surprise on his face as though he is learning something new or finding hidden value in something on the screen.
Share Fallers

ASX 200 insider buys up another $2,000,000 in company stock following Wednesday's 15% crash

This director took Buffett's advice to heart this week.

Read more »

A businessman looking at his digital tablet or strategy planning in hotel conference lobby. He is happy at achieving financial goals.
Broker Notes

Brokers name 3 ASX shares to buy now

Here's why brokers are feeling bullish about these three shares this week.

Read more »

Two happy excited friends in euphoria mood after winning in a bet with a smartphone in hand.
Share Gainers

Why Appen, Mayne Pharma, Playside, and PYC shares are storming higher

These shares are ending the week on a positive note. But why?

Read more »

Man on a laptop thinking.
Broker Notes

Why did Goldman Sachs just downgrade Wesfarmers shares?

The ASX 200 conglomerate has had a ripper run of share price growth. So why is Goldman Sachs downgrading it?

Read more »

A man sits in despair at his computer with his hands either side of his head, staring into the screen with a pained and anguished look on his face, in a home office setting.
Share Fallers

Why AIC Mines, Fletcher Building, Nufarm, and Wesfarmers shares are dropping

These shares are having a tough finish to the week. But why?

Read more »